Recent studies by other groups showed that several CHEK1 inhibitors, such as SCH900776, MU380 and UCN‐01, efficiently sensitized cancer cells to conventional chemo‐radiotherapy irrespective of P53 status,40, 42, 43 supporting our data that AZD7762 significantly augmented the therapeutic effect of RT in all P53 WT, mutated, and deficient cell lines (Figure 5G–I). This evidence concerns the gene TP53 and cancer.